Ting Guo

Ting Guo

Auto-generated profile, based on publicly available information

Ting Guo

Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou, Jiangsu 225300, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
ZLZhifeng Li
Zhifeng Li
DYDazhuang Yang
Dazhuang Yang
TGTing Guo
Ting Guo
MLMei Lin
Mei Lin
Breast cancer (BRCA) is the leading cause of death from malignant tumors among women. Fortunately, however, immunotherapy has recently become a prospective BRCA treatment with encouraging achievements and mild safety profiles. Since the overexpression and aberrant glycosylation of MUC1 (human mucin) are closely associated with BRCA, it has become an ideal target for BRCA immunotherapies. In this review, the structure and function of MUC1 are briefly introduced, and the main research achievements in different kinds of MUC1-mediated BRCA immunotherapy are highlighted, from the laboratory to the clinic. Afterward, the future directions of MUC1-mediated BRCA immunotherapy are predicted, addressing, for example, urgent issues in regard to how efficient immunotherapeutic strategies can be generated.

5 September 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
DNDengyun Nie
Dengyun Nie
TGTing Guo
Ting Guo
MYMiao Yue
Miao Yue
WLWenya Li
Wenya Li
XZXinyu Zong
Xinyu Zong
MLMei Lin
Mei Lin
Cancer is a genetic mutation disease that seriously endangers the health and life of all human beings. As one of the most amazing academic achievements in the past decade, CRISPR/Cas9 technology has been sought after by many researchers due to its powerful gene editing capability. CRISPR/Cas9 technology shows great potential in oncology, and has become one of the most promising technologies for cancer genome-editing therapeutics. However, its efficiency and the safety issues of in vivo gene editing severely limit its widespread application. Therefore, developing a suitable delivery method for the CRISPR/Cas9 system is an urgent problem to be solved at present. Rapid advances in nanomedicine suggest nanoparticles could be a viable option. In this review, we summarize the latest research on the potential use of nanoparticle-based CRISPR/Cas9 systems in cancer therapeutics, in order to further their clinical application. We hope that this review will provide a novel insight into the CRISPR/Cas9 system and offer guidance for nanocarrier designs that will enable its use in cancer clinical applications.

8 November 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YZYinxing Zhu
Yinxing Zhu
MYMiao Yue
Miao Yue
TGTing Guo
Ting Guo
FLFang Li
Fang Li
ZLZhifeng Li
Zhifeng Li
MLMei Lin
Mei Lin
Tanshinone IIA (TanIIA) and gene therapy both hold promising potentials in hepatocellular carcinoma (HCC) treatment. However, low solubility and poor bioavailability of TanIIA limit its clinical application. Similarly, gene therapy with GPC3-shRNA, a type of short hairpin RNAs (shRNAs) capable of silencing the glypican-3 (GPC3) expression, is seriously limited due to its susceptibility to nuclease degradation and high off-target effects. In the present study, polyethyleneimine (PEI)-polyethylene glycol (PEG)-coated mesoporous silica nanoparticles (MSN-PEG) were used as a drug carrier. By encapsulating TanIIA into MSN-PEG, we synthesized MSN-TanIIA-PEG nanoparticles and observed the involved characteristics. This was followed by exploration of antitumor activity on the HepG2 cell lines in vitro. Meanwhile, in order to construct GPC3-shRNA plasmids, a shRNA sequence targeting GPC3 was synthesized and cloned into the pSLenti-U6 vector. Accordingly, the performance of MSN-PEG as a gene transfer carrier for GPC3-shRNA gene therapy of HCC in vitro was evaluated, including transfection efficiency and DNA binding biological characteristics. The results indicated successful encapsulation of TanIIA in MSN-PEG, which had satisfactory efficacy, favorable dispersity, suitable particle size, and sustained release effect. The in vitro anti-HCC effects of nano-TanIIA were greatly improved, which outperformed free-TanIIA in terms of proliferation and invasion inhibition, as well as apoptosis induction of HCC cells. As expected, MSN-PEG possessed excellent gene delivery capacity with good binding, release, and protection from RNase digestion. Using MSN-PEG as a gene carrier, the plasmids were successfully transfected into HepG2 cells, and both the mRNA and protein expressions of GPC3 were significantly downregulated. It was thus concluded that a sustained release TanIIA delivery system for HCC treatment was synthesized and that MSN-PEG could also serve as a gene transfer carrier for gene therapy. More interestingly, MSN-PEG may be a potential delivery platform that combines TanIIA and GPC3-shRNA together to enhance their synergistic effect.

9 July 2022 in Drug Development Research
Verified
Journal Article
Closed access
DYDonglan Yuan
Donglan Yuan
TGTing Guo
Ting Guo
HQHua Qian
Hua Qian
HGHongshan Ge
Hongshan Ge
YZYinling Zhao
Yinling Zhao
HYHong Yu
Hong Yu

20 September 2021 in Analytical Cellular Pathology
Verified
Journal Article
Open access
PDF file
ZLZhifeng Li
Zhifeng Li
FWFujin Wang
Fujin Wang
YZYinxing Zhu
Yinxing Zhu
TGTing Guo
Ting Guo
MLMei Lin
Mei Lin
Breast cancer (BRCA) has severely threatened women’s health worldwide. Radiotherapy is a treatment for BRCA, which applies high doses of ionizing radiation to induce cancer cell death and reduce disease recurrence. Radioresistance is one of the most important elements that affect the therapeutic efficacy of radiotherapy. Long noncoding RNAs (lncRNAs) are suggested to dominate crucial roles in regulating the biological behavior of BRCA. Currently, some studies indicate that overexpression or inhibition of lncRNAs can greatly alter the radioresistance of BRCA. In this review, we summarized the knowledge on the classification and function of lncRNAs and the molecular mechanism of BRCA radioresistance, listed lncRNAs related to the BRCA radioresistance, highlighted their underlying mechanisms, and discussed the potential application of these lncRNAs in regulating BRCA radioresistance.

31 May 2021 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
XBXuefeng Bian
Xuefeng Bian
TGTing Guo
Ting Guo
JZJi Zhang
Ji Zhang
JXJianguo Xia
Jianguo Xia
XFXiaoqian Feng
Xiaoqian Feng
WTWeizhong Tian
Weizhong Tian
Magnetic nanomaterials have recently emerged, playing an increasingly essential role in life science and biomedicine fields, and they exhibited promising potentials in cancer diagnosis and therapy. Also, their use as contrast agents improved various cancer diagnostic imaging sensitivities and accuracy. Magnetic nanomaterials are also exploited as targeted drug carriers to increase the sensitivity and reduce the side effects of chemotherapeutic drugs. Herein, we reviewed the preparation, characterization, and surface modification of various magnetic nanomaterials and their cancer diagnosis and therapy applications.